Anterior pituitary weight, cAMP, cGMP and prolactin levels after combined treatment with estradiol and methylene blue
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
8218149
Knihovny.cz E-resources
- MeSH
- Pituitary Gland, Anterior drug effects growth & development metabolism MeSH
- Cyclic AMP biosynthesis MeSH
- Estrogen Antagonists pharmacology MeSH
- Estradiol pharmacology MeSH
- Cyclic GMP biosynthesis MeSH
- Rats MeSH
- Methylene Blue pharmacology MeSH
- Rats, Wistar MeSH
- Prolactin biosynthesis blood MeSH
- Radioimmunoassay MeSH
- Body Weight drug effects MeSH
- Thyroxine blood MeSH
- Organ Size drug effects MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Cyclic AMP MeSH
- Estrogen Antagonists MeSH
- Estradiol MeSH
- Cyclic GMP MeSH
- Methylene Blue MeSH
- Prolactin MeSH
- Thyroxine MeSH
Male rats received estradiol benzoate in a long acting microcrystalline suspension (1 mg/rat i.m., twice a week), methylene blue (MB) 0.5% in the food and the combination of estradiol and MB. After three weeks, MB partially inhibited the growth response of the anterior pituitary to estradiol and it partially inhibited the increase of cAMP content in anterior pituitary. The increase of anterior pituitary cGMP content was not modified by MB, neither the ratio cAMP/cGMP in the anterior pituitary which, however, decreased after estradiol. This decrease was not modified by MB. On the other hand, the prolactin (PRL) increase in the blood after estradiol was inhibited by MB, although the prolactin content in the anterior pituitary was not. Methylene blue alone did not change blood prolactin concentration, but it unexpectedly elevated blood thyroxine levels and this effect was partially inhibited by simultaneous estradiol treatment.
